Bharat Book

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

Press Release   •   Dec 09, 2013 12:36 IST

Dec 09, 2013 : Bharat Book Bureau presents the new report, on 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013'  also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections.
- A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gram-Positive Bacterial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gram-Positive Bacterial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Rib-X Pharmaceuticals, Inc.
Aphios Corporation
BioMarin Pharmaceutical Inc.
Alchemia Limited
Immtech Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Oragenics, Inc.
Dongwha Pharm Co., Ltd.
Theravance, Inc.
Phynova Group Ltd
Novabiotics Ltd
Priaxon AG
ConjuGon, Inc.
MicuRx Pharmaceuticals, Inc.
AiCuris GmbH & Co. KG
Destiny Pharma Ltd.
Atox Bio Inc.
Microbiotix, Inc.
Cellceutix Corporation
KYORIN Pharmaceutical Co., Ltd.
Lytix Biopharma AS
TAXIS Pharmaceuticals, Inc.
Aureogen Biosciences, Inc.
Cantab Biopharmaceuticals Limited

Table of contents :

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gram-Positive Bacterial Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Gram-Positive Bacterial Infections 9
Gram-Positive Bacterial Infections Therapeutics under Development by Companies 11
Gram-Positive Bacterial Infections Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Gram-Positive Bacterial Infections Therapeutics - Products under Development by Companies 20
Gram-Positive Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Gram-Positive Bacterial Infections Therapeutics Development 24
Rib-X Pharmaceuticals, Inc. 24
Aphios Corporation 25
BioMarin Pharmaceutical Inc. 26
Alchemia Limited 27
Immtech Pharmaceuticals, Inc. 28
Basilea Pharmaceutica Ltd. 29
Oragenics, Inc. 30
Dongwha Pharm Co., Ltd. 31
Theravance, Inc. 32
Phynova Group Ltd 33
Novabiotics Ltd 34
Priaxon AG 35
ConjuGon, Inc. 36
MicuRx Pharmaceuticals, Inc. 37
AiCuris GmbH & Co. KG 38
Destiny Pharma Ltd. 39
Atox Bio Inc. 40
Microbiotix, Inc. 41
Cellceutix Corporation 42
KYORIN Pharmaceutical Co., Ltd. 44
Lytix Biopharma AS 45
TAXIS Pharmaceuticals, Inc. 46
Aureogen Biosciences, Inc. 47
Cantab Biopharmaceuticals Limited 48
Gram-Positive Bacterial Infections - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
PYN-6 - Drug Profile 55
LT-29 - Drug Profile 56
MX-2401 - Drug Profile 57
TD-1792 - Drug Profile 58
Antibiotic Program - Drug Profile 60
MU-1140 - Drug Profile 61
RX-04 - Drug Profile 63
RX-02 - Drug Profile 64
NVB-333 - Drug Profile 65
zabofloxacin - Drug Profile 66
LTX-109 - Drug Profile 68
Marinus - Drug Profile 70
AB-103 - Drug Profile 71
avarofloxacin hydrochloride - Drug Profile 73
ceftobiprole - Drug Profile 76
Hybrid Antibiotics - Drug Profile 79
Antibiotic Program - Drug Profile 80
SLP-0905 - Drug Profile 81
SLP-0906 - Drug Profile 82
SLP-1003 - Drug Profile 83
SLP-0904 - Drug Profile 84
SLP-1004 - Drug Profile 85
BAC Gram -/+ - Drug Profile 86
KRPAM-1977X - Drug Profile 87
KRPAM-1977Y - Drug Profile 88
RX-P792 - Drug Profile 89
Novarifyn - Drug Profile 91
Drug For Gram Positive Wound Infections - Drug Profile 92
MBX-500 - Drug Profile 93
MU-1140-S - Drug Profile 94
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile 96
NAI-107 - Drug Profile 97
Azachryseniums Series - Drug Profile 98
XF-70 - Drug Profile 99
PC-190723 - Drug Profile 100
PBP-539 - Drug Profile 101
Thiolactomycin Analogues - Drug Profile 102
SP-2078 - Drug Profile 103
Sortase A Enzyme Inhibitor - Drug Profile 104
Antibacterial Compounds For Gram Possitive Bacterial Infections - Drug Profile 105
TD-1607 - Drug Profile 106
Ripostatin - Drug Profile 107
Drug For Gram-Positive Bacterial Infections - Drug Profile 108
Broad-Spectrum Antibiotics Targeting Switch Region - Drug Profile 109
Broad-Spectrum Antibiotics Targeting RNA-Exit-Channel - Drug Profile 110
VT-02 - Drug Profile 111
Antibiotic Compounds - Drug Profile 112
PMX-100 - Drug Profile 113
PMX-229 - Drug Profile 114
PMX-519 - Drug Profile 115
PMX-1091 - Drug Profile 117
PMX-1142 - Drug Profile 118

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.